{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:04:46Z","timestamp":1780031086059,"version":"3.53.1"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Hodgkin lymphoma (HL) is a B-cell\u2013derived hematologic malignancy originating from germinal centre B cells. Owing to its remarkable sensitivity to chemotherapy and radiotherapy, HL has become one of the most curable adult malignancies. Over the past decades, treatment regimens such as ABVD and escalated BEACOPP, combined with radiotherapy, have achieved 5-year survival rates exceeding 90% in early-stage patients and long-term remission rates above 75% in advanced-stage disease. However, long-term toxicities associated with conventional therapies\u2014including secondary malignancies, cardiovascular disease, pulmonary fibrosis, and infertility\u2014have increasingly compromised survivors\u2019 quality of life. Meanwhile, approximately 5%\u201310% of patients exhibit primary refractory disease, and 10%\u201330% eventually relapse.In recent years, the emergence of targeted and immunotherapeutic agents, particularly the anti-CD30 antibody\u2013drug conjugate (brentuximab vedotin) and immune checkpoint inhibitors (e.g., PD-1 inhibitors), has profoundly reshaped the therapeutic landscape of HL. This review systematically summarises the epidemiological characteristics and biological foundations of HL, as well as the achievements and limitations of conventional therapies. We place particular emphasis on key clinical trial evidence in recent years and discuss paradigm shifts in four major areas: treatment de-escalation and toxicity reduction in frontline therapy, precision salvage strategies for relapsed\/refractory HL, the evolving role of transplantation, and the application of precision medicine tools such as circulating tumour DNA (ctDNA) and molecular subtyping. We further explore how HL treatment is transitioning from a \u201ccure-oriented\u201d model focused solely on survival to a novel paradigm of \u201cfunctional cure\u201d that balances efficacy with long-term quality of life. We define \u201cfunctional cure\u201d as durable remission with minimal long\u2212term toxicity, preserving organ function and quality of life\u2014a unifying principle of modern HL management. Special attention is given to clinical decision-making in PD-1\u2013exposed patients, emerging therapeutic targets, cellular therapies, and the growing role of real-world evidence. These insights aim to inform future individualised treatment strategies in HL.<\/jats:p>","DOI":"10.3389\/fonc.2026.1855868","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:44:05Z","timestamp":1780029845000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolution of therapeutic paradigms in Hodgkin lymphoma: from \u201ccure-oriented\u201d to \u201cfunctional cure\u201d"],"prefix":"10.3389","volume":"16","author":[{"given":"Chengqian","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis","volume":"15","author":"Huang","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103193","article-title":"Global landscape and trends in lifetime risks of haematologic Malignancies in 185 countries: population-based estimates from Globocan 2022","volume":"83","author":"Sun","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1186\/s12889-025-23469-7","article-title":"Burden of hematologic Malignancies in China from 1990 to 2021: analysis from the Global Burden of Disease Study 2021","volume":"25","author":"Shao","year":"2025","journal-title":"BMC Public Health"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32207-8","article-title":"Classical hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34375","article-title":"Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors","volume":"128","author":"Lu","year":"2022","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/bjh.19840","article-title":"Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: a British Society for Haematology good practice paper","volume":"206","author":"Barrett","year":"2025","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/humupd\/dmad002","article-title":"Reproductive ability in survivors of childhood, adolescent, and young adult Hodgkin lymphoma: a review","volume":"29","author":"Drechsel","year":"2023","journal-title":"Hum Reprod Update"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00262-1","article-title":"Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BRECADD versus EBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial","volume":"26","author":"Ferdinandus","year":"2025","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101271","article-title":"Classic Hodgkin lymphoma: pathobiological features that impact emerging therapies","volume":"71","author":"Alibrahim","year":"2025","journal-title":"Blood Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2019.09.005","article-title":"Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis","volume":"52","author":"Piris","year":"2020","journal-title":"Pathology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2024.05.001","article-title":"The biology of classical Hodgkin lymphoma","volume":"61","author":"Kosydar","year":"2024","journal-title":"Semin Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","volume":"7","author":"van der Weyden","year":"2017","journal-title":"Blood Cancer J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-018-0601-9","article-title":"Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2015.02.002","article-title":"Lymphomagenesis in Hodgkin lymphoma","volume":"34","author":"Matsuki","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2024.10.004","article-title":"Advances in Hodgkin lymphoma research","volume":"31","author":"K\u00fcppers","year":"2025","journal-title":"Trends Mol Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2016.05.001","article-title":"NF-\u03baB deregulation in Hodgkin lymphoma","volume":"39","author":"Weniger","year":"2016","journal-title":"Semin Cancer Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.9.2798","article-title":"Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin\/Reed-Sternberg cells","volume":"97","author":"Hinz","year":"2001","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-017-0474-3","article-title":"Checkpoint inhibitors in hematological Malignancies","volume":"10","author":"Ok","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/path.1725","article-title":"Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin\u2019s lymphoma cells through a mechanism involving Akt kinase and mTOR","volume":"205","author":"Dutton","year":"2005","journal-title":"J Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05881.x","article-title":"Inhibition of the phosphatidylinositol-3 kinase\/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma","volume":"132","author":"Georgakis","year":"2006","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.275","article-title":"S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells","volume":"32","author":"Vrzalikova","year":"2018","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-381905","article-title":"FOXO1 is a tumor suppressor in classical Hodgkin lymphoma","volume":"119","author":"Xie","year":"2012","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/biology12060862","article-title":"Unraveling the immune microenvironment in classic Hodgkin lymphoma: prognostic and therapeutic implications","volume":"12","author":"Georgoulis","year":"2023","journal-title":"Biol (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.10.007","article-title":"Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance","volume":"380","author":"Aldinucci","year":"2016","journal-title":"Cancer Lett"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00589-y","article-title":"PD-1\/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas","volume":"15","author":"Xie","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-025-04047-z","article-title":"PD-L1\/PD-L2 genetic profile in the molecular cytogenetic classification of classic Hodgkin lymphoma","volume":"486","author":"Garc\u00eda-Montenegro","year":"2025","journal-title":"Virchows Arch"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-781989","article-title":"Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma","volume":"130","author":"Liu","year":"2017","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2018-02-833806","article-title":"Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade","volume":"132","author":"Carbone","year":"2018","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001012","article-title":"Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion","volume":"3","author":"Wienand","year":"2019","journal-title":"Blood Adv"},{"key":"B35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/his.14836","article-title":"The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics","volume":"82","author":"Kilsdonk","year":"2023","journal-title":"Histopathology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040884","article-title":"Biology and clinical applicability of plasma thymus and activation-regulated chemokine (TARC) in classical Hodgkin lymphoma","volume":"13","author":"Zijtregtop","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.053199","article-title":"Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma","volume":"97","author":"Plattel","year":"2012","journal-title":"Haematologica"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002206","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022197","article-title":"Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma","volume":"145","author":"Gottschlich","year":"2025","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41568-024-00709-3","article-title":"Liquid biopsies for Hodgkin lymphoma","volume":"24","author":"Lim","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05782-0","article-title":"Circulating tumor DNA assisting lymphoma genetic feature profiling and identification","volume":"103","author":"Wang","year":"2024","journal-title":"Ann Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027355","article-title":"A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA","volume":"146","author":"Pirosa","year":"2025","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01867","article-title":"Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin lymphoma","volume":"42","author":"Heger","year":"2024","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02407","article-title":"Limited, but not eliminated, excess long-term morbidity in stage I-IIA Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine and limited-field radiotherapy","volume":"40","author":"Lagerl\u00f6f","year":"2022","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.323","article-title":"Long-term risk of second Malignancy and cardiovascular disease after Hodgkin lymphoma treatment","volume":"2016","author":"van Leeuwen","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1182\/blood-2024-200662","article-title":"Involved field radiotherapy versus no further treatment in patients with newly diagnosed stage 1A or 2A Hodgkin lymphoma and a \u2018negative\u2019 PET scan after 3 cycles ABVD. Survival and cause of death after a median of 16 years follow-up in the UK RAPID trial","volume":"144","author":"Radford","year":"2024","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/jco.23.01745","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma","volume":"42","author":"Federico","year":"2024","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18594","article-title":"Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC\/LYSA\/FIL H10 and NCRI RAPID trials","volume":"200","author":"Fiaccadori","year":"2023","journal-title":"Br J Haematol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: Final analysis of the randomized German Hodgkin Study Group phase II Nivahl trial","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70205","article-title":"Serum TARC dynamics during anti-PD1-based first-line Hodgkin lymphoma treatment: An analysis from the GHSG Nivahl trial","volume":"9","author":"Plattel","year":"2025","journal-title":"Hemasphere"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1182\/blood-2023-189652","article-title":"Ahod2131: A\u00a0randomized phase 3 response-adapted trial comparing standard therapy with\u00a0immuno-oncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma","volume":"142","author":"Henderson","year":"2023","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01281","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): A multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-151","article-title":"3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma","volume":"146","author":"Herrera","year":"2025","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00203","article-title":"Three-year follow-up of nivolumab-AVD versus brentuximab vedotin-AVD in adolescents with advanced-stage classic Hodgkin lymphoma on S1826","volume":"44","author":"Castellino","year":"2026","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-152","article-title":"Final analysis of the phase III GHSG HD21 trial: PET-guided BRECADD vs. eBEACOPP in advanced-stage classical Hodgkin lymphoma","volume":"146","author":"Ferdinandus","year":"2025","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BRECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): A randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00439","article-title":"Positron emission tomography-guided brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone in older patients with advanced-stage classic Hodgkin lymphoma: A prospective, multicenter, single-arm, phase II cohort of the German Hodgkin Study Group HD21 trial","volume":"43","author":"Ferdinandus","year":"2025","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2024.05.004","article-title":"The management of older patients with Hodgkin lymphoma: Implications of S1826","volume":"61","author":"McKenna","year":"2024","journal-title":"Semin Hematol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287509","article-title":"A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma","volume":"110","author":"Lia","year":"2025","journal-title":"Haematologica"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/cco.0000000000001071","article-title":"Treatment approaches for older Hodgkin lymphoma patients","volume":"36","author":"Br\u00f6ckelmann","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00204","article-title":"Nivolumab-AVD versus brentuximab vedotin-AVD in older patients with advanced-stage classic Hodgkin lymphoma enrolled on S1826","volume":"43","author":"Rutherford","year":"2025","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-1843","article-title":"Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates","volume":"146","author":"Peiqi","year":"2025","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019536","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline CHL therapy for older patients ineligible for chemotherapy","volume":"143","author":"Friedberg","year":"2024","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288033","article-title":"Fit, unfit, or frail? Now easier to tell for Hodgkin lymphoma","volume":"110","author":"Moskowitz","year":"2025","journal-title":"Haematologica"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1153128","article-title":"Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin's lymphoma","volume":"13","author":"Mahdy","year":"2023","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2025.01.004","article-title":"A comparison of mobilization regimens used in Hodgkin lymphoma and factors that influence peripheral blood stem cell mobilization","volume":"27","author":"Gokarn","year":"2025","journal-title":"Cytotherapy"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2024.06.003","article-title":"The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era","volume":"61","author":"Varma","year":"2024","journal-title":"Semin Hematol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2025.12.004","article-title":"Selection of a salvage regimen for relapsed or refractory classic Hodgkin lymphoma in the era of novel therapies","volume":"40","author":"Xiao","year":"2026","journal-title":"Hematol Oncol Clin North Am"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00005-x","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3623","article-title":"Relapsed\/refractory Hodgkin lymphoma after first-line escalated BEACOPDAC: Adverse outcomes are overcome by use of second-line targeted therapy - an international real-world analysis","volume":"146","author":"Jeffers","year":"2025","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2502805","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: A post hoc analysis of KEYNOTE-204 by prior lines of therapy","volume":"66","author":"Kuruvilla","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-1850","article-title":"Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, phase 2 trial","volume":"146","author":"Patel","year":"2025","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5627","article-title":"Transplant-free approach in relapsed Hodgkin lymphoma in children, adolescents, and young adults: A nonrandomized clinical trial","volume":"11","author":"Daw","year":"2025","journal-title":"JAMA Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017118","article-title":"Nivolumab and brentuximab vedotin with or without bendamustine for R\/R Hodgkin lymphoma in children, adolescents, and young adults","volume":"141","author":"Harker-Murray","year":"2023","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005268","article-title":"Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed\/refractory Hodgkin lymphoma","volume":"5","author":"Forlenza","year":"2021","journal-title":"Blood Adv"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: A highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70126","article-title":"Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Mei","year":"2025","journal-title":"Hemasphere"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-025-01257-1","article-title":"Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: A real world analysis from 15 U.S. academic centers","volume":"15","author":"Voorhees","year":"2025","journal-title":"Blood Cancer J"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade8520","article-title":"JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma","volume":"384","author":"Zak","year":"2024","journal-title":"Science"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024487","article-title":"Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma","volume":"144","author":"Nie","year":"2024","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002347","article-title":"Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12943-023-01768-0","article-title":"Epigenetic reprogramming of RUNX3 reinforces CD8\u2009+\u2009T-cell function and improves the clinical response to immunotherapy","volume":"22","author":"Liu","year":"2023","journal-title":"Mol Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-0133","article-title":"Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy","volume":"27","author":"Wang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bjh.18183","article-title":"Chemotherapy after PD-1 inhibitors in relapsed\/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics","volume":"198","author":"Calabretta","year":"2022","journal-title":"Br J Haematol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-1847","article-title":"Bendamustine, gemcitabine, and vinorelbine (BEGEV) regimen followed by ASCT induces durable remissions in PD-(L)1 inhibitor-resistant refractory\/relapsed classical Hodgkin lymphoma: A single-center, long-term study","volume":"146","author":"Liu","year":"2025","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-155","article-title":"First-in-human, open-label, phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with relapsed\/refractory lymphomas: Updated safety, PK, preliminary efficacy and ctDNA analysis from dose escalation","volume":"146","author":"Thiruvengadam","year":"2025","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03640-8","article-title":"Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: A phase\u20091 trial","volume":"31","author":"Nieto","year":"2025","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-015-0188-3","article-title":"AFM13: A first-in-class tetravalent bispecific anti-CD30\/CD16A antibody for NK cell-mediated immunotherapy","volume":"8","author":"Wu","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: Final results of an open-label, randomized, multicenter phase II trial","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-1846","article-title":"Safety and efficacy of MT-601 in relapsed or refractory (R\/R) Hodgkin lymphoma","volume":"146","author":"Abdelhakim","year":"2025","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu387","article-title":"Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"25","author":"Gerrie","year":"2014","journal-title":"Ann Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000575","article-title":"When to use stem cell transplantation for classical Hodgkin lymphoma","volume":"2024","author":"Perales","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.12.944","article-title":"American society of transplantation and cellular therapy clinical practice recommendations for\u00a0transplantation in classical Hodgkin lymphoma","volume":"32","author":"Ahmed","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2025.12.003","article-title":"The role of stem cell transplantation in Hodgkin lymphoma","volume":"40","author":"Alharthy","year":"2026","journal-title":"Hematol Oncol Clin North Am"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02557-7","article-title":"Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed\/refractory Hodgkin lymphoma: A systematic review and meta-analysis","volume":"60","author":"Sureda","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(22)00318-0","article-title":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: A multicentre, phase 2 trial","volume":"10","author":"Herrera","year":"2023","journal-title":"Lancet Haematol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5397","article-title":"Comparable survival with transplant-free approach versus autologous stem cell transplantation in adult relapsed\/refractory classic Hodgkin lymphoma achieving complete remission","volume":"146","author":"Liu","year":"2025","journal-title":"Blood"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027197","article-title":"Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: A joint CIBMTR and EBMT analysis","volume":"146","author":"Perales","year":"2025","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5631","article-title":"Outcomes\u00a0associated with allogeneic hematopoietic stem cell transplantation for relapsed and\u00a0refractory Hodgkin lymphoma in the era of novel agents","volume":"12","author":"Faisal","year":"2023","journal-title":"Cancer Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.045757","article-title":"Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espa\u00f1ol de Linfomas\/Trasplante de M\u00e9dula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70091","article-title":"Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory\/relapsed Hodgkin lymphoma: A retrospective analysis","volume":"207","author":"Mariotti","year":"2025","journal-title":"Br J Haematol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70115","article-title":"Refining the risk stratification in advanced-stage classical Hodgkin lymphoma: A critical analysis of clinical prediction models","volume":"207","author":"Koca","year":"2025","journal-title":"Br J Haematol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02473","article-title":"The advanced-stage Hodgkin lymphoma international prognostic index: Development and validation of a clinical prediction model from the Holistic Consortium","volume":"41","author":"Rodday","year":"2023","journal-title":"J Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-129","article-title":"PET-adaptive BEACOPP- versus ABVD-based therapies for advanced-stage (AS) classic Hodgkin lymphoma (CHL): Survival comparisons leveraging a multi-state model and analyzing the impact of A-HIPI scores across the disease course","volume":"146","author":"Cui","year":"2025","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2500115","article-title":"An individualized prediction model for early-stage classic Hodgkin's lymphoma","volume":"4","author":"Rodday","year":"2025","journal-title":"NEJM Evid"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-1845","article-title":"External validation of the early-stage classic Hodgkin lymphoma (CHL) international prognostication index (E-HIPI) in the German Hodgkin Study Group (GHSG) unfavorable clinical trials","volume":"146","author":"Rodday","year":"2025","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105154","article-title":"Prognostic utility of circulating tumor DNA in classical Hodgkin lymphoma: A systematic review and individual participant data Bayesian meta-analysis","volume":"219","author":"Shahsavand","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-351","article-title":"Circulating tumor DNA analyses of molecular tumor burden are superior to PET-assessed responses in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826","volume":"146","author":"Paczkowska","year":"2025","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031089","article-title":"MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay","volume":"147","author":"Heger","year":"2026","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16514","article-title":"Interim thymus and activation regulated chemokine versus interim (18) F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation","volume":"190","author":"Plattel","year":"2020","journal-title":"Br J Haematol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025015837","article-title":"Serum TARC: A biomarker for early detection or exclusion of relapse in classic Hodgkin lymphoma","volume":"9","author":"Teesink","year":"2025","journal-title":"Blood Adv"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016797","article-title":"Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma","volume":"10","author":"Toner","year":"2026","journal-title":"Blood Adv"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1967\/s002449912471","article-title":"Combined prognostic role\u00a0of TARC and interim (18)F-FDG PET\/CT in patients with Hodgkin lymphoma-real world observational study","volume":"25","author":"Husi","year":"2022","journal-title":"Hell J Nucl Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40364-025-00881-0","article-title":"Soluble cytokines enhance risk prediction across all stages of classical Hodgkin lymphoma","volume":"14","author":"Kred\u00e1tusov\u00e1","year":"2026","journal-title":"biomark Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.Epi-16-1012","article-title":"Elevated serum levels of SCD30 and IL6 and detectable IL10 precede classical Hodgkin lymphoma diagnosis","volume":"26","author":"Levin","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2025.2519524","article-title":"Tight competition for the first-line treatment of Hodgkin\u2019s lymphoma: A comprehensive review of practice-changing developments in recent years","volume":"25","author":"Y\u0131lmaz","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_433502","article-title":"Paradigm shifts in Hodgkin lymphoma treatment: From frontline therapies to relapsed disease","volume":"44","author":"Burton","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70066","article-title":"Newly diagnosed classical Hodgkin lymphoma: Optimizing outcomes in a new therapeutic era","author":"Evens","year":"2025","journal-title":"Hematol Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142292","article-title":"Immune checkpoint molecules in Hodgkin lymphoma and other hematological Malignancies","volume":"17","author":"Alibrahim","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236125","article-title":"Brentuximab-induced peripheral neurotoxicity: A multidisciplinary approach to manage an emerging challenge in Hodgkin lymphoma therapy","volume":"13","author":"Velasco","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2025.104330","article-title":"Update on dermatological toxicities of immune checkpoint inhibitors","volume":"55","author":"Fattore","year":"2025","journal-title":"Presse Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3390\/diseases14020051","article-title":"Reproductive toxicity of immune checkpoint inhibitors in triple-negative breast cancer: A case report with a literature review","volume":"14","author":"Tanase-Damian","year":"2026","journal-title":"Diseases"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100998","article-title":"Applicability of protocols from high-income countries in a resource limited setting; real world data of histopathology, clinical features and long-term outcome of Hodgkin lymphoma in Sri Lanka","volume":"38","author":"Hewamana","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B134","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-025-01673-7","article-title":"Circulating tumor DNA in lymphoma: Technologies and applications","volume":"18","author":"Fu","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1515\/ijamh-2025-0131","article-title":"From cure to care-understanding long-term health risks after Hodgkin's lymphoma treatment in adolescents and young adults","volume":"38","author":"Kearney","year":"2025","journal-title":"Int J Adolesc Med Health"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1855868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:44:15Z","timestamp":1780029855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1855868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":135,"alternative-id":["10.3389\/fonc.2026.1855868"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1855868","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1855868"}}